Valsalva maneuver (VM), although recommended as the guideline-directed emergent treatment for supraventricular tachycardia (SVT), continues to demonstrate suboptimal sinus rhythm restoration rates, partly due to challenges in achieving and maintaining adequate intrathoracic pressure during the maneuver. To address this limitation, a study evaluated the efficacy of a novel handheld Valsalva assist device, designed to help patients attain and sustain target intrathoracic pressures, in improving sinus rhythm restoration rates among 212 patients with SVT.
The study found that after 2 Valsalva maneuvers, 63.2% of participants in the VM with device assist group converted to sinus rhythm within 1 minute compared with 29.2% of participants in the standard VM group. Use of the handheld Valsalva assist device was associated with significantly higher odds of sinus rhythm restoration versus the…
